Production (Stage)
Bolt Biotherapeutics, Inc.
BOLT
$5.94
$0.172.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.64M | 7.69M | 9.78M | 11.17M | 11.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.64M | 7.69M | 9.78M | 11.17M | 11.32M |
| Cost of Revenue | 50.13M | 56.49M | 61.09M | 62.26M | 62.47M |
| Gross Profit | -46.50M | -48.80M | -51.31M | -51.09M | -51.14M |
| SG&A Expenses | 16.45M | 18.46M | 20.04M | 22.00M | 22.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.90M | 75.93M | 82.11M | 85.24M | 86.20M |
| Operating Income | -63.26M | -68.24M | -72.33M | -74.07M | -74.87M |
| Income Before Tax | -63.35M | -63.12M | -65.09M | -66.17M | -63.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.35 | -63.12 | -65.09 | -66.17 | -63.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.35M | -63.12M | -65.09M | -66.17M | -63.03M |
| EBIT | -63.26M | -68.24M | -72.33M | -74.07M | -74.87M |
| EBITDA | -61.54M | -66.46M | -70.51M | -72.23M | -73.03M |
| EPS Basic | -33.14 | -33.06 | -34.17 | -34.82 | -33.27 |
| Normalized Basic EPS | -19.13 | -20.62 | -21.72 | -22.13 | -22.33 |
| EPS Diluted | -33.14 | -33.06 | -34.17 | -34.82 | -33.27 |
| Normalized Diluted EPS | -19.13 | -20.62 | -21.72 | -22.13 | -22.33 |
| Average Basic Shares Outstanding | 7.65M | 7.64M | 7.62M | 7.60M | 7.58M |
| Average Diluted Shares Outstanding | 7.65M | 7.64M | 7.62M | 7.60M | 7.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |